Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal observation of thrombotic events in patients with obstetric antiphospholipid syndrome.

Lupus·2026
Same author

Consolidation Volume Assessed by Quantitative Computed Tomography Predicts the Prognosis of Pneumocystis Pneumonia in Rheumatic Diseases.

Modern rheumatology·2026
Same author

Hot topics in the antiphospholipid syndrome.

Current opinion in immunology·2026
Same author

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Annals of the rheumatic diseases·2026
Same author

The increase of monocyte/high-density lipoprotein cholesterol ratio precedes recurrent thrombosis in patients with APS.

Rheumatology (Oxford, England)·2025
Same author

Neuropsychiatric manifestations in systemic lupus erythematosus and antiphospholipid syndrome: pathophysiology and current insights.

Immunological medicine·2025

Related Experiment Video

Updated: Jul 10, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

[Updates on antiphospholipid syndrome].

Yuichiro Fujieda1

  • 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|July 8, 2026
PubMed
Summary

Antiphospholipid syndrome (APS) management advances with new classification criteria and risk stratification tools. These developments aim to improve diagnosis and personalize treatment for APS patients, moving towards precision medicine.

Keywords:
Antiphospholipid antibodiesAntiphospholipid syndrome

Related Experiment Videos

Last Updated: Jul 10, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Diagnostics

Background:

  • Antiphospholipid syndrome (APS) is defined by recurrent thrombosis and pregnancy issues linked to antiphospholipid antibodies (aPL).
  • Current 2023 ACR/EULAR criteria aid research classification but not clinical diagnosis.
  • Automated immunoassays require standardization for reliable laboratory testing.

Purpose of the Study:

  • To review recent advancements in Antiphospholipid Syndrome (APS) classification, diagnosis, and management.
  • To highlight the integration of new criteria, risk stratification tools, and disease activity assessments.
  • To discuss the potential for precision medicine in APS.

Main Methods:

  • Review of the 2023 ACR/EULAR classification criteria for APS.
  • Analysis of risk stratification methods including quantitative aPL assessment (aPL score, GAPSS) and cardiovascular risk factors.
  • Examination of novel disease activity scores (EAPSDAS) and biomarkers (monocyte-to-HDL ratio).

Main Results:

  • The 2023 ACR/EULAR criteria include microvascular and cardiac valve disease but are for classification, not diagnosis.
  • Quantitative aPL assessment and triple positivity are key for risk stratification.
  • New tools like EAPSDAS and monocyte-to-HDL ratio improve disease activity assessment.
  • Direct oral anticoagulants may be contraindicated in high-risk thrombotic APS patients.

Conclusions:

  • Advances in APS classification and risk stratification are crucial for clinical practice.
  • Integration of quantitative aPL measures and novel biomarkers enhances disease management.
  • These developments pave the way for precision medicine approaches in APS treatment.